<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, April 22, 2020 (HealthDay News) — A model that includes data on clinical and genetic factors and circulating biomarkers may improve risk discrimination for pancreatic cancer, according to a study published online April 22 in Cancer Epidemiology, Biomarkers & Prevention<\/i>.<\/p>\n
Jihye Kim, from the Harvard T.H. Chan School of Public Health in Boston, and colleagues characterized absolute risk models that included clinical factors, germline genetic polymorphisms, and circulating biomarkers within a nested case-control study of 500 pancreatic cancer cases diagnosed after blood collection and 1,091 matched controls.<\/p>\n
The researchers found that the area under the receiver operating characteristic curve estimated by cross-validation was 0.55 for the clinical model, 0.61 for the clinical\/genetic model, and 0.62 for the clinical\/genetic\/biomarker model. The final integrated model identified 3.7 and 2.6 percent of men and women, respectively, who had a risk for pancreatic cancer that was at least three times greater than average in the ensuing 10 years. The risk for developing pancreatic cancer by age 80 years was 4 percent and the 10-year risk at age 70 years was 2 percent for individuals within the top risk percentile.<\/p>\n
“Given the late stage at presentation for most patients with pancreatic cancer, earlier detection approaches are worthy of significant investment as a critical means to reduce mortality from pancreatic cancer, soon to be the second leading cause of cancer death in the United States,” the authors write.<\/p>\n
Two authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n
Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n